Low-Dose Triple Combination Antihypertensive Therapy vs Usual Care and Time at Target Blood Pressure

This secondary analysis of an open-label randomized controlled clinical trial evaluated whether low-dose triple combination antihypertensive therapy helps patients with mild to moderate hypertension to stay at target blood pressure longer than usual care. The triple therapy combination pill contained telmisartan 20 mg, amlodipine 2.5 mg, and chlorthalidone 12.5 mg. In this triple FDC therapy versus usual care, the main endpoints were between-group differences in time at target compared over 24 weeks of follow-up, with time at target defined as percentage of time at target BP. Almost twice as many patients receiving triple pill therapy achieved more than 50% time at target during follow-up (64% vs 37%; P < .001), Patients in the triple therapy group had a longer time at target blood pressure than those in the usual care group (64% vs 43%; P < .001). This held true at all follow-up periods. Triple combination antihypertensive therapy may be an effective way to control hypertension over time, and this study introduces time at target blood pressure as a novel trial outcome. Disclaimer: Lupin makes no representation or warranty of any kind, expressed or implied, regarding the accuracy, adequacy, validity, reliability, availability, or completeness of any scientific information shared by the HCP on the ­­­STAR UPDATE podcast. You should not allow the contents of this to substitute for your own medical judgment, which you should exercise in evaluating the information on this website.